Relative bioavailability and food effect of a paediatric dispersible tablet formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV)

被引：0
|
作者：
Crauwels, Herta [1 ]
Goyvaerts, Nico [1 ]
Vanveggel, Simon [1 ]
Van Solingen, Rodica [1 ]
机构：
[1] Janssen Infect Dis BVBA, Beerse, Belgium
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P032
引用
收藏
页数：1
相关论文
共 50 条
  • [41] QSAR Studies of Non-Nucleoside Reverse Transcriptase Inhibitors: The Hydrophobic Effect
    Douali, L.
    Cherqaoui, D.
    [J]. CURRENT COMPUTER-AIDED DRUG DESIGN, 2006, 2 (01) : 21 - 29
  • [42] No pharmacokinetic drug interaction between the novel non-nucleoside reverse transcriptase inhibitor rilpivirine and the CYP3A probe drug midazolam
    Reinhard, R.
    Hohmann, N.
    Carls, A.
    Mikus, G.
    Haefeli, W.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 : S56 - S57
  • [43] Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels
    De Felipe, B.
    Blanco, A.
    Soriano-Sarabia, N.
    Munoz-Fernandez, M. A.
    Genebat, M.
    Vallejo, A.
    Leal, M.
    [J]. INFECTION, 2008, 36 (03) : 266 - 270
  • [44] Effect of the Substitution of One Nucleoside Analogue by One Non-nucleoside Reverse Transcriptase Inhibitor over Mitochondrial DNA Levels
    B. De Felipe
    A. Blanco
    N. Soriano-Sarabia
    M. Á. Muñoz-Fernández
    M. Genebat
    A. Vallejo
    M. Leal
    [J]. Infection, 2008, 36 : 266 - 270
  • [45] Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission
    Akil, Ayman
    Parniak, Michael A.
    Dezzutti, Charlene S.
    Moncla, Bernard J.
    Cost, Marilyn R.
    Li, Mingguang
    Rohan, Lisa Cencia
    [J]. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2011, 1 (03) : 209 - 222
  • [46] Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing
    Melikian, George L.
    Rhee, Soo-Yon
    Varghese, Vici
    Porter, Danielle
    White, Kirsten
    Taylor, Jonathan
    Towner, William
    Troia, Paolo
    Burack, Jeffrey
    DeJesus, Edwin
    Robbins, Gregory K.
    Razzeca, Kristin
    Kagan, Ron
    Liu, Tommy F.
    Fessel, W. Jeffrey
    Israelski, Dennis
    Shafer, Robert W.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (01) : 12 - 20
  • [47] Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission
    Ayman Akil
    Michael A. Parniak
    Charlene S. Dezzutti
    Bernard J. Moncla
    Marilyn R. Cost
    Mingguang Li
    Lisa Cencia Rohan
    [J]. Drug Delivery and Translational Research, 2011, 1 : 209 - 222
  • [48] Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor
    Sanne, I
    [J]. AIDS, 2000, 14 : S12 - S12
  • [49] Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
    Jordaan, Maryam A.
    Ebenezer, Oluwakemi
    Damoyi, Nkululeko
    Shapi, Michael
    [J]. HELIYON, 2020, 6 (08)
  • [50] Potent suppression of proliferation of carcinoma cells by a novel non-nucleoside reverse transcriptase inhibitor
    Fisch, Alexander
    Schroeder, William
    Smart, Robert
    Patel, Osman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345